The results, when unblinded, stunned the medical community. Among high-risk patients (elderly, asthmatics, pregnant women), AVI-7 reduced hospitalization rates by 76 percent compared to placebo. Even more remarkable, viral sequencing showed zero resistance mutations after 60 days of treatment—something never seen with oseltamivir (Tamiflu).
The European Medicines Agency approved AVI-7 in December 2023 for adults with confirmed influenza A, conditional on kidney monitoring. Within nine months, Phoenix cases had declined by 60 percent in countries where the drug was deployed. anti virus trial
In the spring of 2023, Dr. Elena Márquez, a virologist at the Nordic Institute of Viral Therapeutics, received an urgent alert. A novel strain of influenza—dubbed H17N9 “Phoenix”—had emerged from a wetland in Southeast Asia. Unlike seasonal flu, Phoenix had a mortality rate of nearly 25 percent in healthy adults. The World Health Organization declared a Public Health Emergency of International Concern. The results, when unblinded, stunned the medical community
Elena’s team had spent three years developing a broad-spectrum antiviral compound, code-named AVI-7. It worked differently from existing drugs: rather than targeting viral surface proteins (which mutate rapidly), AVI-7 attached to a host cell protein that the virus needed to replicate. In theory, this made it “resistance-proof.” But theory was not evidence. The European Medicines Agency approved AVI-7 in December
With regulatory approval, 40 healthy volunteers received ascending doses of AVI-7 at a hospital in Oslo. The goal: find side effects. Most reported mild nausea. Two developed temporary liver enzyme elevations, setting a maximum safe dose. No one died. No one got sick from the virus because they were never exposed to it.
But the trial also revealed a serious flaw. In two patients with pre-existing kidney disease, the drug accumulated to toxic levels, causing acute renal failure. Both recovered after dialysis, but the data were clear: AVI-7 could not be given without prior kidney function screening. The drug’s label would need a bolded warning.
Before any human received AVI-7, Elena’s team tested it on human lung cell cultures infected with Phoenix. The drug reduced viral load by 99.9 percent within 48 hours without harming the cells. Next, they used ferrets—the gold standard for flu research—because ferrets cough, sneeze, and develop fever similarly to humans. Treated ferrets recovered fully; untreated ones died or suffered severe pneumonia.